Currently, the maximum expected increase is 3,250.01%. A-shares first-quarter performance preview

Wind data shows that as of March 29, a total of 16 listed companies in the A-share market have disclosed their performance forecasts for the first quarter of 2026, with 14 companies expecting positive results, resulting in a positive forecast ratio of 87.5%. Among them, 4 companies are expected to see slight increases, 1 company is expected to turn a profit, 2 companies are expected to continue losses, and 9 companies are expected to see significant increases.

Specifically, companies such as Fuxiang Pharmaceutical, Wanbangde, and Fuliwang are expected to lead in net profit growth attributable to shareholders of listed companies for the first quarter of 2026. Among them, Fuxiang Pharmaceutical is expected to have a maximum year-on-year net profit growth of 3250.01% for the first quarter of 2026, placing it in the top position.

Highest expected increase exceeds 32 times

Fuxiang Pharmaceutical expects to achieve a net profit attributable to shareholders of listed companies for the first quarter of 2026 to be between 52 million yuan and 75 million yuan, representing a year-on-year growth of 2222.67% to 3250.01%.

Regarding the reasons for the performance increase, Fuxiang Pharmaceutical mentioned in its earnings forecast that during the reporting period, benefiting from the continued improvement in the prosperity of the new energy industry, the demand for power batteries has steadily increased, and the demand for energy storage batteries has rapidly exploded, driving up the demand for upstream lithium battery materials. The company’s lithium battery electrolyte additive business is performing well, with core products such as VC and FEC experiencing both volume and price increases, thus significantly boosting the company’s year-on-year performance growth.

Wanbangde expects to achieve a net profit attributable to shareholders of listed companies of 165 million yuan for the first quarter of 2026, representing a year-on-year increase of 985.4%. The main reason for the performance change is that the company’s strategic transformation from generic drugs to innovative drugs is showing initial results, with positive progress in business expansion during the reporting period, bringing new performance growth points, while continuing to increase R&D efforts. During the reporting period, the company strengthened internal management and increased efforts to recover receivables, effectively accelerating cash flow.

Fuliwang expects to achieve operating revenue of 500 million yuan to 600 million yuan for the first quarter of 2026, representing a year-on-year increase of 47.72% to 77.26%; it expects to achieve a net profit attributable to shareholders of listed companies of 40 million yuan to 50 million yuan, representing a year-on-year increase of 183.84% to 254.81%. The company’s performance growth is mainly due to the increase in operating revenue from its 3C consumer electronics business, which has driven net profit growth. Meanwhile, its subsidiary Nantong Fuliwang has reached breakeven with improved operational efficiency and continuous capacity release, leading to gradually improving business conditions.

Pharmaceutical manufacturing, semiconductor, and other industries

Significant performance growth

From an industry perspective, the pharmaceutical manufacturing and semiconductor sectors are showing significant performance growth.

Among listed companies in the pharmaceutical manufacturing sector, Wanbangde, Fuxiang Pharmaceutical, and Ailisi are expected to see a substantial rebound in performance for the first quarter of 2026.

Ailisi expects a net profit attributable to shareholders for the first quarter to be 590 million yuan, representing a year-on-year increase of 43.73%. The company stated that benefiting from the support and coverage of national medical insurance policies, its sales revenue of commercialized products and promotional service revenue has continuously increased, driving the company’s operational performance to continue climbing.

In the semiconductor sector, companies such as Dinglong Co., Haiguang Information, and Aolaide are expected to report positive performance for the first quarter of 2026. Additionally, Muxi Co., U is expected to reduce its losses year-on-year for the first quarter of 2026.

Haiguang Information expects to achieve a net profit attributable to shareholders of listed companies of 620 million yuan to 720 million yuan for the first quarter of 2026, representing a year-on-year increase of 22.56% to 42.32%. The company stated that during the reporting period, it continuously increased R&D investment, enhancing product competitiveness. The market demand for domestic high-end chips has continued to rise with the increasing demand from the artificial intelligence industry. By continuously increasing R&D investment and optimizing product performance, the company has accelerated product iteration speed, expanding the market landscape of its high-end processor products, achieving significant growth in operating revenue and sustained overall performance growth.

(Source: China Securities Journal)